<DOC>
	<DOCNO>NCT00722852</DOCNO>
	<brief_summary>The purpose study provide replicate evidence safety efficacy 100 mg ketoprofen Diractin® .</brief_summary>
	<brief_title>Study Safety Efficacy Diractin® Treatment Osteoarthritis ( OA ) Knee</brief_title>
	<detailed_description>The study investigate safety efficacy Diractin® relieving sign symptom knee OA , include primary endpoint patient assessment pain .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Ketoprofen</mesh_term>
	<criteria>Informed consent sign date Age &gt; 45 year Class IIII OA knee subject meet American College Rheumatology ( ACR ) clinical classification criterion osteoarthritis knee Skin lesion dermatological disease treatment area Directly indirectly involve conduct administration study Received investigational medicinal product within 30 day prior Screening Visit participation previous clinical study Diractin® Pregnancy lactation Residents psychiatric ward , prison state institution Malignancy within past 2 year Depressive disorder require treatment tricyclic , treatment antidepressant must stable 3 month prior screen throughout study Epilepsy Schizophrenia Neuropathic pain pain condition require chronic use pain medication Known hypersensitivity allergy ( include photoallergy ) NSAID´s include ketoprofen ingredient IMP Preexisting asthma bronchospasm take aspirin NSAIDs Unable discontinue analgesic therapy include opioids , NSAID´s , tramadol , muscle relaxant , gabapentin , pregabalin , duloxetine , venlafaxine , capsaicine drug approve used treatment pain duration study</criteria>
	<gender>All</gender>
	<minimum_age>46 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>